ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma

Low-risk gestational trophoblastic neoplasia including choriocarcinoma is often effectively treated with Methotrexate (MTX) as a first line therapy. However, MTX resistance (MTX-R) occurs in at least ≈33% of cases. This can sometimes be salvaged with actinomycin-D but often requires more toxic combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgiou, Marina, Ntavelou, Panagiota, Stokes, William, Roy, Rajat, Maher, Geoffrey J., Stoilova, Tsvetana, Choo, Josephine A.M.Y., Rakhit, Callum P., Martins, Miguel, Ajuh, Paul, Horowitz, Neil, Berkowitz, Ross S., Elias, Kevin, Seckl, Michael J., Pardo, Olivier E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054653/
https://www.ncbi.nlm.nih.gov/pubmed/35301407
http://dx.doi.org/10.1038/s41388-022-02251-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054653/
https://www.ncbi.nlm.nih.gov/pubmed/35301407
http://dx.doi.org/10.1038/s41388-022-02251-8

Ejemplares similares